Neuropsychotoxicity of abused drugs: Involvement of matrix metalloproteinase-2 and -9 and tissue inhibitor of matrix metalloproteinase-2 in methamphetamine-induced behavioral sensitization and reward in rodents

Journal of Pharmacological Sciences

Volumn 106, Issue 1, 2008, Pages 9-14

  Mizoguchi, Hiroyuki ^a,b,c   Yamada, Kiyofumi ^a,b   Nabeshima, Toshitaka ^a,d  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

^d MEIJO UNIVERSITY   (Japan)

Author keywords

Dopamine; Drugs of abuse; Matrix metalloproteinase; Methamphetamine; Tissue inhibitor of matrix metalloproteinase

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DOPAMINE; GELATINASE A; GELATINASE B; GELATINASE INHIBITOR; METHAMPHETAMINE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

BEHAVIOR; DRUG ABUSE; ELECTROENCEPHALOGRAM; ENZYME DEFICIENCY; NEUROPSYCHOTOXICITY; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; REWARD; RODENT; SENSITIZATION; SHORT SURVEY; TOXICITY;

EID: 38549177310     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FM0070139     Document Type: Short Survey

References (42)

1. Shippenberg TS, Heidbreder Ch. Sensitization to the conditioned rewarding effects of cocaine: pharmacological and temporal characteristics. J Pharmacol Exp Ther. 1995;273:808-815.
2. Berke J, Hyman ST. Addiction, dopamine, and the molecular mechanisms of memory. Neuron. 2000;25:515-532.
3. Ishikawa K, Nitta A, Mizoguchi H, Mouri A, Murai R, Miyamoto Y, et al. Effects of single and repeated administration of methamphetamine or morphine on neuroglycan C gene expression in the rat brain. Int J Neuropsychopharmacol. 2006;9:407-415.
4. Nakajima A, Yamada K, He J, Zeng N, Nitta A, Nabeshima T. Anatomical substrates for the discriminative stimulus effects of methamphetamine in rats. J Neurochem. 2004;91:308-317.
5. Kamei H, Nagai T, Nakano H, Togan Y, Takayanagi M, Takahashi K, et al. Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice. Biol Psychiatry. 2006;59:75-84.
6. Yan Y, Yamada K, Niwa M, Nagai T, Nitta A, Nabeshima T. Enduring vulnerability to reinstatement of methamphetamine-seeking behavior in glial cell line-derived neurotrophic factor mutant mice. FASEB J. 2007;21:1994-2004.
7. Nakajima A, Yamada K, Nagai T, Uchiyama T, Miyamoto Y, Mamiya T, et al. Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity. J Neurosci. 2004;24:2212-2225.
8. Mizoguchi H, Yamada K, Mizuno M, Mizuno T, Nitta A, Noda Y, et al. Regulations of methamphetamine reward by extracellular signal-regulated kinase 1/2/ets-like gene-1 signaling pathway via the activation of dopamine receptors. Mol Pharmacol. 2004;65:1293-1301.
9. Robinson TE, Kolb B. Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. J Neurosci. 1997;17:8491-8497.
10. Nestler EJ. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci. 2001;2:119-128.
11. Yamada K, Nabeshima T. Pro- and anti-addictive neurotrophic factors and cytokines in psychostimulant addiction. Ann N Y Acad Sci. 2004;1025:198-204.
12. Yamada K, Nagai T, Nabeshima T. Drug dependence, synaptic plasticity, and tissue plasminogen activator. J Pharmacol Sci. 2005;97:157-161.
13. Niwa M, Nitta A, Mizoguchi H, Ito Y, Noda Y, Nagai T, et al. A novel molecule "shati" is involved in methamphetamine-induced hyperlocomotion, sensitization, and conditioned place preference. J Neurosci. 2007;27:7604-7615.
14. Nagai T, Yamada K, Yoshimura M, Ishikawa K, Miyamoto Y, Hashimoto K, et al. The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release. Proc Natl Acod Sci U S A. 2004;101:3650-3655.
15. Nagai T, Noda Y, Ishikawa K, Miyamoto Y, Yoshimura M, Ito M, et al. The role of tissue plasminogen activator in methamphetamine-related reward and sensitization. J Neurochem. 2005;92:660-667.
16. Nagai T, Ito M, Nakamichi N, Mizoguchi H, Kamei H, Fukakusa A, et al. The rewards of nicotine: regulation by tissue plasminogen activator-plasmin system through protease activated receptor-1. J Neurosci. 2006;26:12374-12383.
17. Ishikawa K, Nitta A, Mizoguchi H, Mouri A, Murai R, Miyamoto Y, et al. Effects of single and repeated administration of methamphetamine or morphine on neuroglycan C gene expression in the rat brain. Int J Neuropsychopharmacol. 2006;9:407-415.
18. Mizoguchi H, Yamada K, Niwa M, Mouri A, Mizuno T, Noda Y, et al. Reduction of methamphetamine-induced sensitization and reward in matrix metalloproteinase-2 and -9 deficient mice. J Neurochem. 2007;100:1579-1588.
19. Mizoguchi H, Yamada K, Mouri A, Niwa M, Mizuno T, Noda Y, et al. Role of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) in methamphetamine-induced behavioral sensitization and reward: implications for dopamine receptor downregulation and dopamine release. J Neurochem. 2007;102:1548-1560.
20. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci. 2001;2:502-511.
21. Ethell IM, Ethell DW. Matrix metalloproteinases in brain development and remodeling: Synaptic functions and targets. J Neurosci Res. 2007;85:2813-2823.
22. Wright JW, Reichert JR, Davis CJ, Harding JW. Neural plasticity and the brain renin-angiotensin system. Neurosci Biovehav Rev. 2002;26:529-552.
23. Baricos WH, Cortez SL, el-Dahr SS, Schnaper HW. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int. 1995;47:1039-1047.
24. Mannello F, Gazzanelli G. Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. Apoptosis. 2001;6:479-482.
25. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463-516.
26. Rivera S, Tremblay E, Timsit S, Canals O, Ben-Ari Y, Khrestchatisky M. Tissue inhibitor of metalloproteinases-1 (TIMP-1) is differentially induced in neurons and astrocytes after seizures: evidence for developmental, immediate early gene, and lesion response. J Neurosci. 1997;17:4223-4235.
27. Szklarczyk A, Lapinska J, Rylski M, Mckay RD, Kaczmarek L. Matrixmetalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J Neurosci. 2002;22:920-930.
28. Vaillant C, Didier-Bazes M, Hurter A, Bein MF, Thomasset N. Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum. J Neurosci. 1999;19:4994-5004.
29. Lo EH, Wang X, Cuzner ML. Extracellular proteolysis in brain injury and inflammation: role for plasminogen activations and matrix metalloproteinases. J Neurosci Res. 2002;69:1-9.
30. Nagy V, Bozdagi O, Matynia A, Balcerzyk M, Okulski P, Dzwonek J, et al. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J Neurosci. 2006;15:1923-1934.
31. Krekoski CA, Neubauer D, Graham JB, Muir DL. Metalloproteinase-dependent predegeneration in vitro enhances axonal regeneration within a cellular peripheral nerve grafts. J Neurosci. 2002;22:10408-10415.
32. Monard D. Cell-derived proteases and protease inhibitors as regulators of neurite outgrowth. Trends Neurosci. 1988;11:541-544.
33. Uhm JH, Dolley NP, Oh LY, Yong VW. Oligodendrocytes utilize a matrix metalloproteinases, MMP-9, to extend processes along an astrocyte extracellular matrix. Glia. 1998;22:53-63.
34. Reeves T, Prins ML, Zhu JP, Povlishock JT, Phillips LL. Matrix metalloproteinases inhibition alters functional and structural correlates of deafferentation-induced sprouting in the dentate gyrus. J Neurosci. 2003;12:10182-10189.
35. Brown TE, Forquer MR, Cocking DL, Jansen HT, Harding JW, Sorg BA. Role of matrix metalloproteinases in the acquisition and reconsolidation of cocaine-induced conditioned place preference. Learn Mem. 2007;14:214-223.
36. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci. 1995;15:4102-4108.
37. Khoshbouei H, Sen N, Guptaroy B, Johnson L, Lund D, Gnegy ME, et al. N-terminalphosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol. 2004;2:387-393.
38. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry. 2002;159:1642-1652.
39. Bowers MS, McFarland K, Lake RW, Peterson YK, Lapish CC, Gregory ML, et al. Activator of G protein signaling 3: a gatekeeper of cocaine sensitization and drug seeking. Neuron. 2004;42:269-281.
40. 2+-evoked release of [3H]-dopamine from striatal synaptosomes by dopamine (D2) agonists and antagonists. J Pharmacol Exp Ther. 1987;241:27-33.
41. Lindgren N, Xu Z-QiD, Herrera-M M, Haycock J, Hokfelt T, Fisone G. Dopamine D2 receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum. Eur J Neurosci. 2001;13:773-780.
42. Kim YS, Choi DH, Block ML, Lorenzl S, Yang L, Kim YJ, et al. A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB J. 2007;21:179-187.